Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijcard.2015.08.178 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Functional Efficacy of Tissue-Engineered Small-Diameter Nanofibrous Polyurethane Vascular Grafts Surface-Modified by Methacrylated Sulfated Alginate in the Rat Abdominal Aorta.
ACS Appl Mater Interfaces
December 2024
Department of Tissue Engineering, School of Advanced Technologies in Medicine, Royan Institute, Tehran 16635-148, Iran.
Improved design to imitate natural vascular scaffolds is critical in vascular tissue engineering (VTE). Smooth muscle cells originating from surrounding tissues require larger pore sizes relative to those of endothelial progenitor cells found in the bloodstream. Furthermore, biofunctionalized scaffolds mimic the microenvironment, cellular function, and tissue morphogenesis.
View Article and Find Full Text PDFRedefining Calciphylaxis as a Uniquely Bone Forming Subcutaneous C5b-9-Mediated Microvascular Injury Syndrome Associated With Localized Subcutaneous and Systemic Complement Pathway Activation.
Am J Dermatopathol
December 2024
Pathologist, Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY.
Background: Microvascular thrombosis is key to the pathogenesis of calciphylaxis. C5b-9-mediated microvascular injury reflective of complement pathway activation could be a key pathophysiologic event.
Methods: We conducted a retrospective multicenter study of 24 patients who have had biopsy-supported calciphylaxis from the 2010-2022 data base from Emory where C5b-9 immunohistochemistry (IHC) had not been conducted and the 2019-2023 data base from Cornell where C5b-9 IHC was done as part of the routine calciphylaxis work up.
Randomized Comparison of Novel Low-Dose Sirolimus-Eluting Biodegradable Polymer Stent vs Second-Generation DES: TARGET-IV NA Trial.
J Am Coll Cardiol
October 2024
Clinical Trial Center, Cardiovascular Research Foundation, New York, New York, USA; NewYork-Presbyterian Hospital/Columbia University Medical Center, New York, New York, USA.
Background: Drug-eluting stents (DESs) with controlled antiproliferative drug release reduce restenosis risk, but durable polymers can delay healing and inhibit reendothelialization. The Firehawk biodegradable polymer sirolimus-eluting stent (BP-SES) has a fully biodegradable sirolimus-containing polymer coating localized to recessed abluminal grooves on the stent surface and delivers roughly one-third the drug dose of other DESs.
Objectives: We report the primary results of the TARGET-IV NA (Firehawk Rapamycin Target Eluting Coronary Stent North American Trial) randomized controlled trial comparing clinical outcomes with BP-SES vs currently used second-generation DESs.
Ex vivo nanoscale abluminal mapping of putative cargo receptors at the blood-brain barrier of expanded brain capillaries.
Fluids Barriers CNS
October 2024
Department of Biomedicine, Aarhus University, Aarhus C, 8000, Denmark.
Receptor mediated transport of therapeutic antibodies through the blood-brain barrier (BBB) give promise for drug delivery to alleviate brain diseases. We developed a low-cost method to obtain nanoscale localization data of putative cargo receptors. We combine existing ex vivo isolation methods with expansion microscopy (ExM) to analyze receptor localizations in brain microcapillaries.
View Article and Find Full Text PDFHigh-Density Lipoprotein Mimetic Peptide 4F Reduces Toxic Amyloid-Beta Exposure to the Blood-Brain Barrier Endothelium in Alzheimer's Disease Transgenic Mice.
Mol Pharm
November 2024
Department of Pharmaceutics and Brain Barriers Research Center, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55455, United States.
Article Synopsis
- * The HDL mimetic peptide 4F shows promise as a treatment, as it significantly reduces the blood-to-brain influx of Aβ in both wild-type and APP/PS1 transgenic mice.
- * 4F lowers Aβ-induced activation of the p38 pathway in endothelial cells, suggesting it may help protect the BBB and reduce Aβ accumulation, offering potential therapeutic avenues for AD.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!